Clinical Trials Logo

Metformin clinical trials

View clinical trials related to Metformin.

Filter by:

NCT ID: NCT04947020 Active, not recruiting - Rectal Cancer Clinical Trials

dataBase for Analysis of Rectal Cancer Oncological Results

BARO
Start date: August 1, 2021
Phase:
Study type: Observational

The data will be obtained from 10 tertiary centers located in Poland (Cracow - coordinating center, Warsaw - 3 centers, Sosnowiec, Szczecin, Bydgoszcz, Lublin, Gdansk, Poznan) and 5 foreign centers. The analyses will include patients with rectal cancer operated on between 2013-2019. A database in MS Excel is prepared that consists of following data: - Type of neoadjuvant treatment (if any) - Time-interval between the end of neoadjuvant treatment and surgery - Type of surgery - Staging of rectal cancer i.e. (y)pTNM - Number of retrieved lymph nodes - Number of lymph nodes with metastases - R classification (R0, R1, R2) - Preoperative medications (metformin, statins, NSAIDs, anticoagulants) - Recurrence date and type (local, systemic, both diagnosed at the same time) - Date of death or date of last follow-up visit The aims of the study are following: 1. Establishing whether neoadjuvant treatment (PSCR or chemoradiotherapy) influences number of retrieved lymph nodes in rectal cancer 2. Establishing whether time-interval between the end of PSCR and surgery influences lymph node yield 3. Establishing the prognostic value of lymph node ratio - validation of the previously calculated cutoff point at the level of 0.41 4. Determining independent prognostic factors in rectal cancer - in particular related to medications taken before the operation, metformin and anti diabetic drugs in the first place

NCT ID: NCT04885426 Recruiting - Colorectal Adenoma Clinical Trials

Metformin for the Prevention of CRA Recurrence

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

NCT ID: NCT04581447 Recruiting - Diabetes Clinical Trials

Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care

DiabOUT
Start date: January 7, 2021
Phase: Phase 3
Study type: Interventional

This study is a randomized trial that evaluates the effect of metformin addition or not to standard care on the duration of diabetes remission after bariatric surgery.

NCT ID: NCT04477590 Recruiting - Exercise Training Clinical Trials

Interactions of Medicine and Exercise With Meal Timing

MMET
Start date: June 7, 2022
Phase: N/A
Study type: Interventional

To analyze the effects of altering the time of ingestion of participants' habitual medication (i.e., metformin, statins, ARAII/IACE) and meals around the time of exercise training (exercise fasted or fed) on the improvement of metabolic syndrome factors (hypertension, insulin sensitivity, dyslipidemia, and obesity). There will be a preliminary study of the effects of training "time-of-day" on the primary study outcomes.

NCT ID: NCT04377451 Completed - Obesity Clinical Trials

Metformin in Dengue With Obesity

MeDO
Start date: July 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to investigate the effect of metformin as host-directed therapy in obese/overweight patients with dengue Primary Objective To evaluate the safety and tolerability of metformin in obese/overweight young adults and children with dengue Secondary Objectives - To assess the effect of metformin therapy in obese/overweight patients with dengue on physiological, clinical and virological parameters - To assess the immunomodulation effects of metformin therapy in obese/overweight patients with dengue - To assess difference in gene expression between treatment group compared to non-treatment population

NCT ID: NCT04284722 Not yet recruiting - Type 2 Diabetes Clinical Trials

Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery

Start date: February 2020
Phase: Phase 4
Study type: Interventional

Evaluation of the effect of peri-operative continuation of oral metformin therapy on the incidence of perioperative hyperglycemia compared to standard preoperative cessation of oral metformin therapy 24h before surgery.

NCT ID: NCT04194515 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Gut Microbiota and Bile Acids in Type 2 Diabetes Mellitus

Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

The investigators will evaluate the stool microbiota, serum and fecal bile acid composition, and changes in blood glucose and lipid profile before and after one month of metformin or YH1 treatment.

NCT ID: NCT03708549 Recruiting - Schizophrenia Clinical Trials

Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients

Start date: December 1, 2021
Phase: Phase 4
Study type: Interventional

Berberine is an isoquinoline alkaloid extracted from medicinal herbs, has been demonstrated to produce beneficial effects on diabetes and hyperlipidemia, fewer study reported its modification on lipid metabolism in schizophrenia. Metformin, have been used for metabolic abnormalities in schizophrenia, findings from these studies indicated that they did have some effect,which are still in experimental stage.This study is aim to compare the efficacy and safety of berberine and metformin for preventing metabolic dysfunction in schizophrenia patients.

NCT ID: NCT03618472 Completed - Metformin Clinical Trials

Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.

NCT ID: NCT03590262 Recruiting - Clinical trials for Type 1 Diabetes Mellitus

Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

Aim Evidence of a possible connection between gut microbiota and several physiological processes linked to type 1 diabetes is increasing. However, the effect of multistrain probiotics in people with type 1 diabetes remains unclear. This study investigated the effect of metformin as add-on therapy on glycemic control and other diabetes-related outcomes in people with type 1 diabetes.